Our Company - Contributing with pride and passion, beyond expectations
Our Company - Contributing with pride and passion, beyond expectations

Our Company

Contributing with pride and passion, beyond expectations

Tools content (print, share, increase/decrease text size):

 

Middle area:

Sanofi ranks 3rd on the 2012 Access to Medicine Index

 

December 7, 2012
 

 

A third place in recognition of the company’s long-term strategy for improving access to healthcare and its efforts to raise the hopes of patients around the world.
 

 

Sanofi is noted for its research efforts in neglected tropical diseases (1), high-incidence infectious diseases (2) in developing countries, and chronic diseases (3), as well as the broad range of molecules in its pipeline. Sanofi is also well positioned for its leadership in public policy, sustainable philanthropy and drug donations through the Sanofi Espoir Foundation, together with its organization and system for managing differentiated prices and its capacity to work with local governments.

As a responsible healthcare company, Sanofi is committed to continuing its efforts to reduce inequalities in access to healthcare, medicines and vaccines. 

 

The Access to Medicine Index is published every two years by the Access to Medicine Foundation

The ATM index ranks pharmaceutical companies on their commitments, performance, innovation, and transparency in seven areas of activity (4) that are considered key to improving access to medicines, vaccines and healthcare technologies for the world’s poorest communities.

The goal of the ATM Index is to provide pharmaceutical companies, investors, governments, academics, non-governmental organizations and the general public with independent, impartial and reliable information about pharmaceutical companies’ efforts to improve global access to healthcare and medicine. This index acts as a benchmark for investors that pay close attention to corporate social responsibility criteria.

 

 
 

 
References:

(1) Sleeping sickness, leishmaniasis, Chagas disease, Buruli ulcer
(2) Malaria, tuberculosis, dengue
(3) Diabetes, mental and cardiovascular diseases
(4) Management, Public Policy, R&D, Pricing, Patents, Capacity, Donations in 2009

 
 

© Sanofi 2004-2014 - All rights reserved - Update: October 10, 2014

  • Site complies with W3C WCAG 2.0 (new window, in english)